Skip to content

Rifaximin EP Impurity D

Rifaximin EP Impurity D

Product Description
CAT No.
ALN-R027005
CAS No.
NA
Mol. F.
C43H49N3O12
Mol. Wt.
799.9
Stock
Please Inquire
RFQ
Smiles : CC1=CC2=NC3=C(C(NC(/C(C)=C\C=C\[C@]4(O)C)=O)=C(O)C5=C3C6=C(O[C@](C)(O/C=C\[C@]([H])(OC)C([H])(C)[C@@]([H])(OC(C)=O)[C@]([H])(C)[C@]([H])(O)[C@@](C)([H])C4=O)C6=O)C(C)=C5O)N2C=C1
Inchi : InChI=1S/C37H47NO12.Na/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41;/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46);/b11-10-,14-13-,17-12-;/t16-,18+,19+,20+,25-,29-,30+,33+,37-;/m0./s1

Structural elucidation of the Rifaximin Ph. Eur. Impurity H

Riccardo Stradi, Donatella Nava, Marino Nebuloni, Barbara Pastura, ElenaPininJournal of Pharmaceutical and Biomedical Analysis Volume 51, Issue 4, 11 March 2010, Pages 858-865

Structure Elucidation of Two Unknown Oxydic Degradation Impurities of Rifaximin

chao liu, chang-qin hu\xa0 and shao-hong jin – Asian Journal of Chemistry; Vol. 23, No. 7 (2011), 3252-3256

Development and validation of rp-hplc method for the estimation of rifaximin in bulk and in tablet dosage form

T.sudha, P.V.hemalatha, V.R.ravikumar,r.jothi, M.radhakrishnan – Asian Journal of Pharmaceutical and Clinical Research Vol.2 Issue 4, October-December 2009

Request For Quotation

Related Products